other material
confidence high
sentiment neutral
materiality 0.50
Sonoma Pharma enters $2.07M ATM stock offering with Ladenburg Thalmann
Sonoma Pharmaceuticals, Inc.
- At Market Issuance Sales Agreement with Ladenburg Thalmann for up to $2,070,463 of common stock.
- Ladenburg receives 3% commission on gross proceeds; Company reimburses up to $40,000 in expenses.
- Sales under existing S-3 effective Nov 20, 2023; prospectus supplement filed Sep 26, 2025.
- Company not obligated to sell any shares; no assurance of price, amount, or timing of sales.
- Agreement terminates upon sale of all shares or earlier per its terms.